Disclosures for "Correction of Duchenne Muscular Dystrophy Mutations by CRISPR/Cas9 Gene Editing Using Homology-Independent Targeted Integration"
-
The institution of Dr. Nicolau has received research support from Muscular Dystrophy association. The institution of Dr. Nicolau has received research support from American Brain Foundation. The institution of Dr. Nicolau has received research support from American Neuromuscular Foundation.
-
An immediate family member of Dr. Vetter has received personal compensation for serving as an employee of Nikon Instruments. The institution of Dr. Vetter has received research support from Diverge Translational Science Laboratory.
-
Dr. Stephenson has received personal compensation for serving as an employee of Forge Biologics. Dr. Stephenson has stock in Forge Biologics.
-
Miss Dufresne has nothing to disclose.
-
Ms. Frair has nothing to disclose.
-
Ms. Trecha has nothing to disclose.
-
Miss Sarff has nothing to disclose.
-
Dr. Flanigan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apic Bio. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AavantiBio. Dr. Flanigan has stock in 4D Molecular Therapeutics. The institution of Dr. Flanigan has received research support from Abeona Therapeutics. The institution of Dr. Flanigan has received research support from Sarepta Therapeutics. The institution of Dr. Flanigan has received research support from Astellas Therapeutics. Dr. Flanigan has received intellectual property interests from a discovery or technology relating to health care.